On December 15, Ascletis Pharma-B (01672) announced positive top-line results from its independently developed oral small molecule IL-17 inhibitor, ASC50, in a Phase I clinical trial in the United States. The primary objective of the trial was to evaluate the safety, tolerability, and pharmacokinetic characteristics of ASC50. Forty-six healthy subjects received different doses of ASC50 (10 mg to 600 mg). The results showed that the elimination half-lives of ASC50 at each dose were 43, 89, 91, 87, 104, and 85 hours, supporting once-daily or potentially weekly oral administration.

Furthermore, ASC50 demonstrated significant targeted binding efficacy after administration, with IL-17A levels remaining elevated up to day 7 at higher doses. Safety and tolerability were good at all dose levels, with all adverse events being mild and no serious adverse events reported.

Based on these positive results, ASC50 will advance to the next phase of clinical development, conducting multi-dose escalation studies for mild to moderate plaque psoriasis. The drug has received compound patent protection in the United States and globally, with the patent expiring in 2043.

https://finance.eastmoney.com/a/202512153591772367.html